Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
10.69
+0.61 (6.05%)
At close: Mar 31, 2026, 4:00 PM EDT
10.51
-0.18 (-1.68%)
After-hours: Mar 31, 2026, 7:36 PM EDT
Elicio Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Elicio Therapeutics stock have an average target of 17, which predicts a 59.03% increase from the current stock price of 10.69.
Price Target: $17 (+59.03%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Elicio Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $17 | Strong Buy | Maintains | $13 → $17 | +59.03% | Mar 13, 2026 |
| Rodman & Renshaw | Rodman & Renshaw | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +59.03% | Mar 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $13 | Strong Buy | Maintains | $10 → $13 | +21.61% | Jul 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $10 | Strong Buy | Reiterates | $10 | -6.45% | Apr 2, 2025 |
| Jones Trading | Jones Trading | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | -15.81% | Oct 31, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.54
from -2.58
EPS Next Year
-1.43
from -1.54
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.35 | -1.47 | |
| Avg | -1.54 | -1.43 | |
| Low | -1.69 | -1.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.